Pfenex Inc. (NYSE : PFNX) announced that the company will regain the full rights to PF582, a biosimilar candidate to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE